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ABSTRACT 
Context:  Citrus fruits contain unique flavanones.  One of the most abundant of the flavanones, 
hesperidin, has been shown to prevent bone loss in ovariectomized rats. 
Objective: The objective of the study was to measure the  effect of hesperidin with or without calcium 
supplementation on bone calcium retention in postmenopausal women. 
Design.  The study was a double blind, placebo-controlled, randomized order cross-over design of 500 g 
hesperidin with or without 500 mg calcium supplement  in 12 healthy postmenopausal women.  Bone 
calcium retention was determined from urinary excretion of the rare isotope, 41Ca, from bone. 
Results.  Calcium plus hesperidin, but not hesperidin alone, improved bone calcium retention by 5.5% (p 
< 0.04). 
Conclusion.  Calcium supplementation (Calcilock®), in combination with hesperidin, is effective at 
preserving bone in postmenopausal women. 
 
 
 
  
Both environment and genes influence bone mass and  determine  the risk of developing 
osteoporosis (1, 2),  Women are at high risk for bone fracture after menopause due to an increased loss of 
bone in response to  decreased estrogen  secretion.(1)   It  is well established that nutrition has an 
important role in bone health.  Research has shown that calcium, vitamin D, and several micronutrients 
are essential for maintaining optimum bone mineral density and strength. (3)  Fruits and vegetables 
containing various polyphenolic compounds, especially flavonoids, have been associated with improved 
bone mineral density in part because of an effect on cell signaling pathways that regulate the cells 
responsible for bone formation and resorption  (4-6)   
Citrus fruits contain hesperidin (hesperetin-7-O-rutinoside), a flavanone that is especially 
abundant in oranges (31-43.2 mg/100 g).   Preclinical studies in rats and mice have shown positive effects 
of hesperidin on various bone parameters (7).   Dietary supplementation hesperidin (0.5%, w/w) of 3 
month old rats resulted in increased bone mass and the same diet in 6 month old rats prevented 
ovariectomy-induced bone loss (8).  When the diet of twenty month old male rats was supplemented with 
0.5% hesperidin for three months, both femoral bone density and trabecular bone volume increased (9) .   
 Because there is a paucity of studies of the effect of hesperidin on bone in humans, we studied 
the effect of hesperidin and its interaction with dietary calcium on reducing bone loss in twelve healthy 
post-menopausal women using the isotopic tracer, 41Ca, method (10). 
Study Subjects 
 Healthy women who were at least 4 years postmenopausal as a result of natural or surgical  menopause  
established by questionnaire and validated by  serum FSH , were enrolled in the study.  Women who were 
on estrogen replacement therapy, treatment for osteoporosis, or taking dietary calcium supplements were 
not eligible for the study.  All participants gave written informed consent and the study was approved by 
the Purdue University and Indiana University Purdue University Institutional Review Boards. 
Study Design and Methods 
The study design was randomized order, double blind cross-over with one baseline and three 
treatment phases. (Fig. 1)    Interventions consisted of 4 biscuits daily that contained either, 1) 500 g 
hesperidin, 2) 500 g hesperidin + 500 mg calcium as CALCILOCK® or 3) placebo (Nestle Research and 
Development, Maipu, Chile).  Study interventions were assigned to each subject in random order.  With 
three interventions (A, B, and C) there were six possible orders (ABC, ACB, BAC, BCA, CAB).  A file 
with the six interventions was randomly sorted to give the orders for the first six subjects.  The process 
was repeated for the six additional subjects.  Biscuits were provided at the beginning of each intervention 
phase. Subjects were instructed to consume 1 serving (two biscuits) in the morning and 1 serving in the 
evening for each day of the 50 day intervention phase.  Each intervention phase was followed by a 50 day 
wash out period.  An initial 50 day baseline preceded the first treatment period (Fig 1).  During each 50 
day period subjects collected 24 h urine every 10 days (5 collections per phase).   Subjects submitted 4 
day diet records including 3 week days and 1 weekend day at the end of each intervention phase.  Records 
were analyzed using the Nutrition Data System for Research (NDSR, version 2011, Minneapolis, MN, 
USA).   
 At the end of each baseline, intervention and washout phase there was a clinical visit. Subjects 
returned any uneaten products. Fasting (>8h) serum and urine samples  were collected to evaluate mineral 
and safety biochemistry and  biochemical markers of bone turnover including serum C- telopeptide 
(Crosslaps® ELISA  Immunodiagnostic Systems, Fountain Hills AZ, USA, CV = 4.2%), parathyroid 
hormone ( two-site immunoassay, Nichols Institute Diagnostics, San Juan, Capistrano, CA, 
USA(CV=7.1%), total 25(OH) D ( LC-MS/MS, Novilytic LLC, North Webster IN, USA,), urine 
deoxypyridinoline (Microvue EIA, Quidel Corp., San Diego, CA, USA, CV=6.9%).  Serum and urine 
creatinine, calcium and  inorganic phosphorus  were measured by routine chemistry.  Anthropometric 
measures were taken using standard weight scales, stadiometer and calipers. Total body, dual hip and 
lumbar spine bone mineral densities were measured at the baseline visit (iDXA, software version 4.3e, 
GE Lunar Corp., Madison WI, USA)  
All urine samples were prepared for 41Ca analysis as previously described (11).  Briefly, calcium 
was precipitated by adjusting the pH to at least 10 using ammonium hydroxide and then adding 
ammonium oxalate to form calcium oxalate (CaCsO4).  The supernatant was decanted and the precipitate 
was collected on filter paper and dried.  The 41Ca:Ca ratios were determined in the filtrate by Accelerator 
Mass Spectrometry (PRIME Lab, Purdue University, W. Lafayette, IN USA). 
Statistical Analysis 
  The power of the protocol was based on the ability to detect changes in 41Ca excretion in  urine.  With at 
least 10 subjects there was 80% power to detect a 10% improvement in net calcium retention.  Daily 
urinary 41Ca during an intervention was compared with the change predicted from baseline and non-
intervention periods.  Daily urinary 41Ca:Ca ratios were transformed using the natural logarithm.  For each 
subject a linear regression using non-intervention data was used to predict ratios for intervention periods. 
For each subject, deviations of the observed intervention value from the corresponding predicted value 
were averaged to determine the intervention effects.  The values were averaged for all 12 subjects and 
95% confidence intervals were calculated.  The estimates and confidence intervals were expressed as 
relative change in bone calcium retention (%) as described previously (12).  Statistical significance 
(p<0.05) indicates significant deviation from the predicted change.  The bootstrap method was used to 
verify the accuracy of the asymptotic approximations used.  Biomarkers were secondary outcomes and 
were analyzed using ANOVA methods based on the crossover design.  
 
Results 
Fourteen women were screened for the study.  Twelve women age 66.3 y, post-menopausal 16.8 
y, and BMI of 25.7 kg/m2 were enrolled in the study. (Table 1) All 12 women completed all baseline, 3 
intervention, and 3 washout phases.   Mean compliance with the consumption of the biscuits was 92.5% . 
A 5.5% improvement in net calcium bone retention was found for hesperidin with the calcium 
supplement (p=0.04, Fig 2).  For hesperidin alone and for placebo, the changes were not statistically 
significant (p=0.34, P=0.39).   The 95% confidence interval for the combination treatment did not contain 
zero and thus can be considered an effective treatment for increasing net bone calcium retention.   No 
significant intervention effects were found for the biomarkers or mineral biochemistry  (Table 2) other 
than PTH was less with the combination treatment than with hesperidin alone or placebo.   
There was no indication that dietary intake varied from treatment to treatment when macro and 
micronutrients from the diet records plus supplements were analyzed other than calcium that was greater 
in the hesperidin plus Calcilock® phase (Table 3).   
 
Discussion 
 
In this randomized order, placebo-controlled, double-blind clinical trial in postmenopausal women, 
hesperidin plus a nutritional supplement (Calcilock®) formulated into biscuits improved net bone calcium 
retention by 5.5%, but hesperidin alone had no benefit.  This study employed the novel and sensitive 
approach of measuring urinary appearance of the rare isotope, 41Ca, from bone to determine the effect of 
interventions on net bone calcium retention (or loss) relative to predicted values from non-intervention 
periods and compared with a placebo period.  All three intervention periods and recovery periods were 
tested in each of the 12 participants in 350 days.  The more traditional approach of a parallel arm study 
measuring changes in bone mineral density would have involved an intervention period of 2 or more 
years and 60 or more participants per arm to have similar power to our study.  Thus, both methods give an 
estimate of changes in bone calcium due to intervention, but the power of the cross-over design and the 
sensitivity of 41Ca analysis greatly reduce the time and number of participants required. However, bone 
densitometry could give site specific changes in bone, whereas, calcium tracers reflect whole body 
metabolism.  The longer intervention periods in bone density trials span several bone remodeling cycles 
which may be more reflective of the long term impact of an intervention.  The 50 day intervention periods 
that we used in this study span a little more than one remodeling cycle, and therefore, may reflect a 
remodeling transient which could mean a one time benefit that could disappear upon cessation (13).  
Nevertheless, this is a useful screening approach to identify effective interventions to pursue in the longer, 
more expensive trials monitoring bone mineral density. 
The benefit of hesperidin plus Calcilock®  intervention on bone calcium retention of 5.5% 
theoretically is equivalent to a benefit in net calcium balance or total bone mineral content (BMC) as 
calcium is a constant fraction of BMC.  This provides a practical and substantial countermeasure to 
women stable to menopause who on average lose 0.5 to 2.0% BMC annually, depending on the bone site 
(14).  The lack of benefit of the hesperidin alone intervention suggests the benefit is due to calcium rather 
than the hesperidin, though this was not directly tested.  Consistent with our observed lack of effect of 
500 mg hesperidin, an unpublished 2 y randomized, controlled trial described in a conference proceeding 
(15) found no benefit to BMD at any site including total hip, femoral neck, lumbar spine, or whole body.  
A benefit of calcium of this magnitude in women with average intake of approximately 1 g/d may be 
surprising given the plateau intake for calcium retention in this age group is approximately 1.2 g/d (16).  
Yet calcium supplementation has benefits to calcium retention and bone parameters in similar populations 
(17,18).  
The dose and form of hesperidin as well as the inflammatory status of the subjects may influence 
effects on bone.  The same dose of hesperidin as used in this study was effective in reducing two 
inflammatory markers, C-reactive protein and serum amyloid A protein in patients with metabolic 
syndrome (19).  Hesperitin-7-glucoside, a metabolite of hesperidin, may have been more effective than 
hesperidin because it is more bioavailable (20, 21).  The current study provides little mechanistic insight 
as the purported effects of flavonoids on osteoblast and osteoclast differentiation were not studied.  For 
example, Kim et al, (22) showed hesperitin suppressed NF-kappaB activation.  We powered our study for 
the main outcome which is a more sensitive measure than for biochemical markers of bone turnover or 
regulators of calcium metabolism.  The bone resorption marker, deoxypyridinoline, was suppressed by 
hesperidin in a male senescent rat model (9).  Serum PTH (p<0.05) was much less in the active 
intervention, a classic response to increased dietary calcium (17). 
In summary, in postmenopausal women stable to menopause, Calcilock®, a supplement including 
500 mg calcium with hesperidin, but not hesperidin alone, was effective in improving bone calcium 
retention.  The benefit may be exclusively due to calcium, but a limitation of the study was lack of a 
calcium alone intervention so an interaction cannot be ruled out.  The novel use of a rare calcium isotope, 
41Ca, allowed multiple interventions to be directly compared in a cross-over design in the same subjects 
with substantially reduced intervention duration and sample size than a traditional trial of change in bone 
mineral density. 
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